When an 82-year-old woman arrived at an Athens hospital with two months of visible blood in her urine, her CT scans revealed a 5.5-centimeter mass protruding from the upper pole of her left kidney. Radiologists classified the lesion as a Bosniak category IV cyst—a designation that carries a roughly 90 percent chance of being a malignant renal cell carcinoma. The expectation, in most hospitals, would have been a swift trip to the operating room for removal of the tumor, and likely the entire kidney. Instead, the clinical team at Attikon General Hospital paused, threaded a needle through her skin under CT guidance, and pulled out a tiny core of tissue that would overturn the grim diagnosis. The mass was not cancer, but a renal oncocytoma, a rare benign tumor that perfectly mimics kidney cancer on every standard imaging exam.
Renal oncocytomas represent only about 5 to 9 percent of all epithelial kidney tumors, and they arise not from the proximal tubule cells that spawn the common clear cell carcinomas, but from the intercalated cells of the distal collecting ducts. Under the microscope, these tumors are composed of large, polygonal cells packed with mitochondria, giving the cytoplasm a granular, intensely eosinophilic appearance. The cells are remarkably uniform, arranged in solid nests or tubules, and lack the chaotic nuclear irregularities that characterize their malignant cousins. Yet this peaceful histology is invisible to a CT scanner. Even multiphase contrast-enhanced imaging cannot reliably tease apart an oncocytoma from the far more dangerous chromophobe renal cell carcinoma, which shares a similar cellular lineage but can metastasize and kill.
The diagnostic trap has long posed a dilemma. “If you rely only on imaging, you will operate on many patients who do not need surgery,” says Areti Kalfoutzou, the lead author of a new case report published in Oncotarget. In the Greek patient, the answer came from a percutaneous core biopsy, a technique that is gaining traction but remains underutilized for renal masses. The core was subjected to a panel of immunohistochemical stains that function like a molecular fingerprinting system. The tumor cells lit up for E-cadherin and cyclin D1, showed focal positivity for cytokeratin 7 (CK7), and were negative for CD117, carbonic anhydrase IX (CAIX), vimentin, and RCC marker. That profile—particularly the negative CAIX, which is strongly expressed in clear cell carcinoma, and negative CD117, which often marks chromophobe tumors—is a beacon for oncocytoma. The stains tell a story that the radiologist cannot see: a benign plotline hidden inside a malignant-looking mass.
Armed with a definitive tissue diagnosis, the hospital’s multidisciplinary tumor board faced a decision that would have seemed unthinkable a decade ago. Instead of radical surgery, they recommended percutaneous cryoablation, a minimally invasive procedure in which thin probes are inserted directly into the tumor and supercooled argon gas freezes the cells to death. Cryoablation is usually reserved for patients with small renal cancers who cannot withstand surgery, but here the logic was different. The tumor was biologically indolent, the patient was 82, and a partial or radical nephrectomy would carry significant perioperative risk and potential loss of kidney function. Two years later, annual follow-up scans show no trace of recurrence, and the woman’s remaining kidney hums along normally.
The molecular biology elevating this case from anecdote to paradigm is the same that fuels the broad push toward precision oncology. Renal oncocytomas frequently harbor mutations in mitochondrial genes, and some even exhibit rearrangements of the TFE3 gene, further blurring the line with chromophobe carcinoma. In fact, hybrid oncocytic/chromophobe tumors are a recognized entity that sits precariously between benign and malignant behavior. Pathologists now deploy a combination of morphology, immunostaining, and sometimes cytogenetic analysis to separate these entities. The Oncotarget report reviews the literature showing that the CK7/CK20 immunoprofile, coupled with cyclin D1 and CD117 status, can achieve high diagnostic accuracy, but it requires expertise that still clusters in academic centers. The wider community, Kalfoutzou argues, needs to normalize the biopsy step before sharp instruments enter the picture.
That argument carries weight in an era of overdiagnosis. Incidental small renal masses are discovered with increasing frequency as abdominal imaging for other reasons proliferates. Studies estimate that up to 30 percent of small, surgically removed renal tumors turn out to be benign on final pathology—a sobering statistic when one considers the permanent loss of nephrons. A biopsy-first strategy, integrated with advanced immunohistochemistry and molecular testing, could spare thousands of patients each year from unnecessary nephrectomies. It could also redirect resources toward those who truly need oncologic surgery, shortening wait times and reducing the downstream costs of chronic kidney disease.
The Greek team’s experience does not suggest that every Bosniak IV lesion should be biopsied rather than resected. Many are aggressive cancers, and in younger, fit patients, surgery remains the standard. But for elderly patients or those with significant comorbidities, the calculus changes. The report emphasizes individualized management, a phrase that gets tossed around often but here is applied with rigorous logic. The tumor board weighed tumor size and growth kinetics, imaging features, core biopsy histology and immunophenotype, patient age, baseline renal function, and the risk of a missed diagnosis against the morbidity of intervention. That is the essence of modern cancer care—not reflexively cutting out everything that looks suspicious, but integrating every piece of data to match the treatment intensity to the biological threat.
As renal oncocytoma research advances, new imaging tracers such as ⁹⁹mTc-sestamibi SPECT are showing promise in distinguishing benign oncocytic tumors from renal carcinomas based on mitochondrial density, but they are not yet routine. Until such techniques mature, the path from image to diagnosis will still run through a small piece of tissue captured by a slender biopsy needle. The Oncotarget case report lands as a practical reminder that sometimes the most sophisticated technology in oncology is not a million-dollar scanner, but a simple decision to ask the tumor what it really is before reaching for the scalpel.
Subject of Research: People
Article Title: Renal oncocytoma: Α case report and literature review
News Publication Date: July 6, 2026
Web References: https://doi.org/10.18632/oncotarget.28893 ; https://www.oncotarget.com/archive/v17/
References: Kalfoutzou A, et al. Renal oncocytoma: Α case report and literature review. Oncotarget. 2026;17. DOI: 10.18632/oncotarget.28893
Image Credits: Copyright: © 2026 Kalfoutzou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Keywords: cryoablation, image-guided biopsy, kidney neoplasms, minimally invasive surgery, renal oncocytoma, Bosniak classification, immunohistochemistry, chromophobe renal cell carcinoma
